Triple-negative breast cancers (TNBCs) are immunohistochemically defined as a subset of breast cancers that are negative for human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) [1] and account for 15–20% of breast cancers [2]. Here, ERBB2 is linked to triple-negative breast carcinoma.